Table 1.
Associations between genetically predicted and measured levels of a protein and LDL cholesterol levels.
| Protein | CIS* | Odds-ratio† | 95% CI | p-value | Beta‡ | 95% CI | p-value | |
|---|---|---|---|---|---|---|---|---|
| ApoE | Y | 1.07 | (1.04–1.11) | 6.2×10−6 | 0.43 | (0.36 – 0.50) | 4.9 ×10−30 | |
| ApoE2 | Y | 1.10 | (1.07–1.14) | 4.1×10−10 | 0.21 | (0.14 – 0.29) | 1.2 ×10−7 | |
| ApoE3 | Y | 1.12 | (1.08–1.15) | 4.5×10−12 | 0.37 | (0.30 – 0.45) | 7.0 ×10−22 | |
| ApoE4 | Y | 1.07 | (1.04–1.11) | 5.7×10−6 | 0.29 | (0.21 – 0.36) | 6.6 ×10−13 | |
| Catalase | N | 1.07 | (1.04–1.10) | 1.1×10−5 | 0.05 | (−0.03 – 0.13) | 0.26 | |
| Granulin | N | 1.09 | (1.06–1.13) | 1.0×10−8 | −0.02 | (−0.10 – 0.06) | 0.66 | |
| IL-27 | N | 1.07 | (1.03–1.10) | 3.6×10−5 | 0.00 | (−0.07 – 0.08) | 0.90 |
Footnotes:
*
Indicates whether the association was significant (p<0.01) when analyses were limited to SNPs located within 1 Mb of the gene locus.
†
EHR genetic association based on logistic regression analyses for an association with a diagnosis of “Hyperlipidemia” (n=8,511 cases and 13,436 controls) adjusting for birth year, gender, eMERGE site, genotyping platform and 3 principal components.
‡
MDCS epidemiological validation showing the change in LDL-C levels based on a linear regression model adjusting for age, sex and plate.